New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 8, 2013
12:32 EDTFIO, SIG, SHLD, AYI, MDCO, CY, MONOn The Fly: Midday Wrap
Stocks on Wall Street were lower again at midday as investors shift their focus from the fiscal cliff to the fourth-quarter earnings season, set to unofficially kick off after the closing bell when Dow component Alcoa (AA) reports. Expectations for the earnings season are muted, with S&P 500 companies forecast to post earnings growth of just 2.8% for the quarter, according to Thomson Reuters. Profit-growth estimates were sharply reduced from the expected growth rate of 9.2% called for at the end of September, according to FactSet. The averages have drifted lower on fairly light volume, indicating a lack of buying rather than intense selling, as investors may be content to wait to see how the earnings season develops before stepping back in... ECONOMIC EVENTS: In the U.S., the NFIB small-business-optimism index rose to 88.0 in December from 87.5 in November. In Europe, zone-wide unemployment hit a new record rate of 11.8% in November, though the European Commission also separately reported that its December Economic Sentiment Indicator improved by 1.3 points in the euro area, to 87.0, and remained generally unchanged at 88.4 in the broader EU. In Asia, Japan said it will use its foreign reserves to continue to buy bonds issued by the European Stability Mechanism to help weaken the yen... COMPANY NEWS: Sears Holdings (SHLD) said late Monday that CEO Louis D’Ambrosio will step down due to family health reasons and be replaced in that role by Eddie Lampert, its chairman of the board and largest shareholder. Sears also forecast adjusted earnings for Q4 that beat consensus expectations but shares fell about 5% near noon... Among companies reporting earnings after yesterday's close or before today's open, Monsanto (MON) advanced and Acuity Brands (AYI) declined... MAJOR MOVERS: Among the notable gainers were The Medicines Company (MDCO), up 11% after announcing results for a Phase 3 trial of one of its drugs, and Signet Jewelers (SIG), up 9% after reporting its holiday season same-store sales rose 3.3% and issuing earnings guidance. Among the noteworthy losers were Cypress Semiconductor (CY), down 9% after cutting its Q4 earnings forecast, and Fusion-io (FIO), which fell 8% after William Blair downgraded the stock to Market Perform... INDICES: Near noon, the Dow was down 68.23, or 0.51%, to 13,316.06; the Nasdaq was down 15.69, or 0.51%, to 3,083.12; and the S&P 500 was down 7.46, or 0.51%, to 1,454.43.
News For SHLD;MON;MDCO;SIG;CY;AYI;FIO From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 >>
November 18, 2015
06:03 EDTMONBayer says not looking to sell crop chemicals business, Reuters reports
Bayer (BAYRY) says its Bayer CropScience unit is an "integral part" of the company and that the division is not for sale, Reuters reports. Bayer's comments come after Monsanto (MON) executives said that it is in internal discussions about tie-ups in the industry. Reference Link
06:01 EDTMONMonsanto studying possibility for consolidation in agrochem sector, Reuters says
Subscribe for More Information
November 17, 2015
16:26 EDTMONOn The Fly: Top stock stories for Tuesday
Stocks on Wall Street see-sawed throughout the day and eventually finished the day mixed, with solid earnings reports from both Wal-Mart (WMT) and Home Depot (HD) helping the Dow notch a small gain while the S&P recorded a small loss. The averages looked to be set to extend yesterday's advance, but weakened during the afternoon following news of a stadium evacuation in Europe that unsettled investors and put a halt to the rally. The market struggled into the close but avoided a big selloff as headlines crossed that police in Germany found no explosives at the site of the game cancellation in Hanover. ECONOMIC EVENTS: In the U.S., the consumer price index rose 0.2% in October, as expected. When food and energy prices are stripped out, the "core" CPI also rose 0.2%, also matching the consensus forecast. Industrial production slid 0.2% in October, versus expectations for it to have risen 0.1%. Capacity utilization came in as expected at 77.5%. NAHB's home builder sentiment index fell 3 points to 62 in November, versus expectations for a reading of 64. COMPANY NEWS: Shares of Wal-Mart advanced 3.5% to $59.92 after the world's largest retailer reported better than expected quarterly earnings and gave a fiscal year profit outlook that was higher than expected at the midpoint of the company's range. Another retail giant and fellow Dow member, Home Depot, gained 4.4% to $126.18 while TJX (TJX), owner of the TJ Maxx and HomeGoods brands, rose nearly 4% to $68.18 after their own better than expected quarterly reports. Missing out on the retail rally, however, was Dick's Sporting Good (DKS), which tumbled 9.4% to $36.96 after giving guidance for the holiday quarter and fiscal 2015 that missed consensus estimates. MAJOR MOVERS: Among the notable gainers was Airgas (ARG), which jumped $31.17, or 29.39%, to $137.35 after agreeing to be acquired by Air Liquide for $143 per share. Also higher was Syngenta (SYT), which advanced $6.69, or 9.24%, to $79.06 after Monsanto (MON) Chief Operating Officer Brett Begemann told reporters the company is weighing another attempt at acquiring the Swiss firm. Among the noteworthy losers were GNC (GNC), Vitamin Shoppe (VSI), and Natural Health (NHTC), which dropped a respective 6.4%, 5%, and 15.4% after the Department of Justice said in a media advisory that it would announce actions related to dietary supplements sales and unlawful ads. Shares in the publicly traded companies came off their lows, but did not fully recover heading into the close, after the agency announced that its criminal case was charging USPlabs and that its five civil cases were against a number of smaller businesses. Also lower was SunEdison (SUNE), which fell $1.54, or 33.74%, to $3.02, with Oppenheimer attributing the selloff to "unsubstantiated rumors" regarding its liquidity and Deutsche Bank saying language in Vivint Solar's (VSLR) quarterly filing around SunEdison debt financing could concern some investors who are focused on the balance sheet. Additionally, Adeptus (ADPT) declined 22.3% to $46.50 after an NBC affiliate published an investigative report scrutinizing billing practices at freestanding emergency rooms in Colorado. INDEXES: The Dow rose 6.49, or 0.04%, to 17,489.50, the Nasdaq gained 1.40, or 0.03%, to 4,986.02, and the S&P 500 slipped 2.75, or 0.13%, to 2,050.44.
13:19 EDTMONMonsanto weighs another takeover offer for Syngenta, Bloomberg reports
Monsanto (MON) is weighing another takeover attempt for Syngenta (SYT) after China National Chemical Corporation made an offer for Syngenta, Bloomberg reports. Monsanto is having internal discussions over the benefits of a new offer, the report says, citing comments from COO Brett Begemann in front of reporters in St. Louis. Reference Link
12:54 EDTMONMonsanto targets over 1.3B acres of technology upgrades from platforms by 2025
During Monsanto company's Biennial Investor Event, the company will note that it operates from a global footprint of more than 400M acres currently using its technologies, with the company anticipating more than 1.3B acres of next-generation technology upgrades by 2025. Approximately 800M acres of upgrades are expected to come from its core growth drivers like Intacta RR2 PRO soybeans, Roundup Ready 2 Xtend soybeans and from its global corn portfolio. The company anticipates another 550M-900M acres of technology upgrades from its new growth platforms, including 300M-400M acres from the Climate FieldView digital agronomic platform and 250M-500M acres from the BioAg Alliance with Novozymes.
12:51 EDTMONMonsanto sees more than 20% CAGR in ongoing EPS from end of FY16 to FY19
Subscribe for More Information
12:48 EDTMONMonsanto confirms FY16 EPS view of $5.10-$5.60, consensus $5.33
Subscribe for More Information
11:34 EDTMONMonsanto to host two day biennial investor event
Subscribe for More Information
11:27 EDTMONMonsanto still sees earnings doubling by 2019, Bloomberg reports
Monsanto (MON) COO Brett Begemann told reporters ahead of the company's biennial investor event tomorrow that his company still expects its earnings to double between 2014 and 2019, according to Bloomberg. Begemann added that Monsanto management is internally discussing making another takeover approach to Syngenta (SYT), the news agency added. Begemann noted that acquisitions are not needed for Monsanto to double earnings by 2019. He expects 20% earnings growth in 2017, 2018 and 2019, Bloomberg reports.
11:24 EDTMONSyngenta jumps 3% after Monsanto says discussing another approach
Subscribe for More Information
11:23 EDTMONMonsanto COO says internally discussing another Syngenta approach
Subscribe for More Information
07:56 EDTCYUBS to hold a conference
Global Technology Conference is being held in San Francisco on November 16-18 with webcasted company presentations to begin on November 17 at 10:45 am.; not all company presentations may be webcasted. Webcast Link
November 16, 2015
17:10 EDTMONSoros took stake in Paypal, liquidated Herbalife stake
Soros Fund Management gave a quarterly update on its stakes in a filing this afternoon. NEW STAKES: Paypal (PYPL), CIT Group (CIT), Schlumberger (SLB), Kraft Heinz (KHC), and Amazon (AMZN). INCREASED STAKES: Allergan (AGN), Lions Gate (LGF), Energen (EGN), Southwest Airlines (LUV), and Qunar Cayman Islands (QUNR). DECREASED STAKES: LyondellBasell (LYB), YPF (YPF), Time Warner Cable (TWC), Dow Chemical (DOW), and Monsanto (MON). LIQUIDATED STAKES: Herbalife (HLF), Lennar (LEN), DR Horton (DHI), United Continental (UAL), and Nice Systems (NICE).
11:35 EDTSHLDDillard's sinks to 52-week low after joining chorus of 'disappointed' retailers
Shares of Dillard's (DDS), a retailer of fashion apparel, cosmetics and home furnishing, are falling to their worst level in a year after the company became the latest in its industry to report lower than expected third quarter results. WHAT'S NEW: This morning, Dillard's reported Q3 earnings per share of $1.19 and revenue of $1.435B, narrowly missing analysts' consensus estimates of $1.20 and $1.49B, respectively. Same-store sales for the quarter fell 4%. Total merchandise sales decreased 3% for the 13-week period ended October 31. Weaker performing categories were men's apparel and accessories and ladies' accessories and lingerie with notable weakness in home and furniture the company explained. Dillard's Chief Executive Officer, William T. Dillard, II, stated, "We are disappointed with our third quarter sales performance and in the resulting decline in profit. Share buyback remained a high priority, and we repurchased $175 million of stock under our share repurchase program." WHAT'S NOTABLE: Gross margin from retail operations improved 11 basis points of sales for the 13 weeks ended October 31 compared to the prior year third quarter. Consolidated gross margin for the 13 weeks ended October 31 declined 30 basis points of sales compared to the prior year third quarter. The disparity between retail and consolidated gross margin performance is attributable to increased revenue at CDI, which is a substantially lower margin business. Inventory increased 6% at October 31 compared to November 1, 2014. For FY15, the company expects capital expenditures of $150M. PRICE ACTION: In late morning trading, Dillard's fell $5.81, or 7.5%, to $71.79 on more than three times its average daily trading volume. Earlier in the session, the stock hit a fresh 52-week low of $68.05. Including today's pull back, the shares have lost about 36% over the past 12 months. OTHERS TO WATCH: Other apparel, cosmetics and home furnishing retailers include Macy's (M), Kohl's (KSS), JC Penny (JCP), Sears (SHLD) and Nordstrom (JWN).
07:50 EDTCYUBS to hold a conference
Subscribe for More Information
November 13, 2015
14:52 EDTMDCOFederal Circuit overturns District Court decision on Angiomax patents
Subscribe for More Information
13:57 EDTMDCOAppeals court vacates decision invalidating Medicines Co. Angiomax patents
Subscribe for More Information
13:38 EDTMDCOThe Medicines Co. jumps 9% following reports of court decision
Shares of The Medicines Co. jumped after reports surfaced that an appeals court vacated the decision invalidating Angiomax patents.
November 12, 2015
18:29 EDTMONSyngenta rejects initial $42B bid from ChemChina, Bloomberg says
Syngenta rejected that offer citing regulatory risk, however Syngenta and ChemChina are continuing talks, Bloomberg added. Syngenta is also talking to other suitors and has had previous discussions with both DuPont (DD) and Monsanto (MON) earlier this year. Reference Link
November 11, 2015
10:46 EDTMDCOAlnylam and The Medicines Co. reports trial results with ALN-PCSsc
Alnylam (ALNY) and The Medicines Company (MDCO) reported results from their ongoing Phase 1 clinical trial with ALN-PCSsc in an oral presentation at the American Heart Association Scientific Sessions 2015. ALN-PCSsc is an investigational RNAi therapeutic targeting PCSK9 - a genetically validated protein regulator of LDL receptor metabolism - being developed for the treatment of hypercholesterolemia. As reported previously, subcutaneous administration of ALN-PCSsc resulted in an up to 83% lowering of LDL-C, with an up to 64 +/- 5 percent mean maximum reduction, comparable to published results for anti-PCSK9 MAbs. In new results, the effects of ALN-PCSsc were found to be highly durable, with clinically significant and clamped reductions in LDL-C, supportive of a potential bi-annual subcutaneous dose regimen. Specifically, an up to 53 percent maximal and 47% least squares mean reduction in LDL-C was achieved at day 180 after just a single, low volume injection. In addition, ALN-PCSsc was shown to reduce a number of atherogenic lipids, including lipoprotein - or "Lp" - and total cholesterol, which are associated with increased risk of cardiovascular disease. ALN-PCSsc was generally well tolerated with no clinically significant drug-related adverse events. The development leadership of ALN-PCSsc has now transferred from Alnylam to The Medicines Company, who expects to initiate the ORION-1 Phase 2 study by the end of 2015.
1 | 2 | 3 >>

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use